Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.744 EUR
−7.03 M EUR
2.94 M EUR
6.13 M
About ADVICENNE
Sector
CEO
Didier Laurens
Headquarters
Paris
Website
Founded
2007
ISIN
FR0013296746
FIGI
BBG00JB78ZQ6
Advicenne SA is a pharmaceutical company, which engages in the development of innovative treatments in Nephrology. It develops treatment for both adults and kids. The company was founded in 2007 by Luc-André Granier and Caroline Roussel-Maupetit and is headquartered in Paris, France.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of ALDVI is 1.990 EUR — it hasn't changed in the past 24 hours. Watch ADVICENNE stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on EURONEXT exchange ADVICENNE stocks are traded under the ticker ALDVI.
ALDVI stock has risen by 16.51% compared to the previous week, the month change is a −5.91% fall, over the last year ADVICENNE has showed a −14.96% decrease.
We've gathered analysts' opinions on ADVICENNE future price: according to them, ALDVI price has a max estimate of 4.00 EUR and a min estimate of 4.00 EUR. Watch ALDVI chart and read a more detailed ADVICENNE stock forecast: see what analysts think of ADVICENNE and suggest that you do with its stocks.
ALDVI reached its all-time high on Feb 16, 2021 with the price of 15.956 EUR, and its all-time low was 0.828 EUR and was reached on Jul 26, 2024. View more price dynamics on ALDVI chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
ALDVI stock is 2.88% volatile and has beta coefficient of −0.42. Track ADVICENNE stock price on the chart and check out the list of the most volatile stocks — is ADVICENNE there?
Today ADVICENNE has the market capitalization of 24.44 M, it has increased by 19.16% over the last week.
Yes, you can track ADVICENNE financials in yearly and quarterly reports right on TradingView.
ADVICENNE is going to release the next earnings report on Mar 27, 2025. Keep track of upcoming events with our Earnings Calendar.
ADVICENNE revenue for the last half-year amounts to 1.91 M EUR, despite the estimated figure of 2.42 M EUR. In the next half-year revenue is expected to reach 2.00 M EUR.
ALDVI net income for the last half-year is −5.53 M EUR, while the previous report showed −3.30 M EUR of net income which accounts for −67.82% change. Track more ADVICENNE financial stats to get the full picture.
No, ALDVI doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 26, 2024, the company has 20.00 employees. See our rating of the largest employees — is ADVICENNE on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ADVICENNE EBITDA is −7.10 M EUR, and current EBITDA margin is −230.46%. See more stats in ADVICENNE financial statements.
Like other stocks, ALDVI shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ADVICENNE stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ADVICENNE technincal analysis shows the strong buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ADVICENNE stock shows the sell signal. See more of ADVICENNE technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.